Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy

Acute myeloid leukaemia is prevalent in older patients that are often ineligible for intensive chemotherapy and treatment options remain limited with azacitidine being at the forefront. Azacitidine has been used in the clinic for decades, however, we still lack a complete understanding of the mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Symeonidou, Vasiliki, Metzner, Marlen, Usukhbayar, Batchimeg, Jackson, Aimee E., Fox, Sonia, Craddock, Charles F., Vyas, Paresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421974/
https://www.ncbi.nlm.nih.gov/pubmed/36051087
http://dx.doi.org/10.1002/jha2.527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421974/
https://www.ncbi.nlm.nih.gov/pubmed/36051087
http://dx.doi.org/10.1002/jha2.527

Ejemplares similares